Abstract: A pharmaceutical composition for treatment of a tumor expressing at least one of a plurality of receptor proteins including CD24, Axl, DC-SIGN, Tyro3, MER, MerTK TIM-1, TIM-4, TLR3, TLR8, RIG-1, and MDA5. The pharmaceutical composition includes either a purified viral RNA of an oncolytic Zika virus in a liposome and a pharmaceutically acceptable carrier, or a pharmaceutically acceptable carrier and a unit dosage form of an oncolytic Zika virus.

Abstract: Disclosed herein are methods and devices for pathogen or antibody detection using unmodified signaling substances with or without unlabeled detection reagents. Unmodified signaling substance include, but are not limited to, a molecule, a material or a part of a material that is not modified with an antibody, an antigen, a pathogen, a DNA probe or an aptamer molecule. Unlabeled detection reagent refers to an antibody, an antigen, a pathogen, a DNA probe, or an aptamer that is not labeled with a signaling molecule such as enzyme, biotin, streptavidin, fluorescence or chemiluminescence probe, etc.

Abstract: CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject.

Abstract: CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject.

Abstract: CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject.